No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
XRAY240517P30000
- 1.72
- +0.28+19.44%
15min DelayClose May 13 15:59 ET
1.72High1.68Low
1.68Open1.44Pre Close2 Volume25 Open Interest30.00Strike Price340.00Turnover77.28%IV-0.99%PremiumMay 17, 2024Expiry Date1.82Intrinsic Value100Multiplier3DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.7682Delta0.1352Gamma13.42Leverage Ratio-0.0863Theta-0.0023Rho-10.31Eff Leverage0.0089Vega
Intraday
- 5D
- 1D
News
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Globus Medical (GMED) and DENTSPLY SIRONA (XRAY)
Stifel Nicolaus Sticks to Its Hold Rating for DENTSPLY SIRONA (XRAY)
Dentsply Sirona to Participate in Upcoming Investor Conferences
Dentsply Sirona Is Maintained at Neutral by Goldman Sachs
Dentsply Sirona Is Maintained at Neutral by Goldman Sachs
Express News | Goldman Sachs Maintains Neutral on Dentsply Sirona, Lowers Price Target to $30
Dentsply Sirona Is Maintained at Outperform by Evercore ISI Group
Dentsply Sirona Is Maintained at Outperform by Evercore ISI Group
Comments
The company's low growth and lack of profits have led to a stock price drop. A revenue growth acceleration might boost the share price. However, the real benefit for shareholders will be if the company starts making profits. Despite recent gains, the returns over the last three years have been disappointing.
DENTSPLY SIRONA (NASDAQ:XRAY) Shareholders Have Endured a 32% Loss From Investing in the Stock Three Years Ago 1
DENTSPLY SIRONA's decreasing capital employment and flat returns are concerning. The stock's decline may reflect investor pessimism about these trends. The analysis does not see the traits of a multi-bagger in this stock.
DENTSPLY SIRONA's decision to pay a dividend amidst a reported loss is unsettling. It's not an ideal choice for long-term buy and hold investors.
1
Investors predict limited future growth for the company, reflected by its low P/S ratio. The pessimism around its revenue prospect contributes to its undervalued stock.
DENTSPLY SIRONA, currently undervalued with steady price trends, could make a solid investment. Despite modest growth projections, aspects like capital structure and management track record could be behind its undervaluation.
Read more